Vucina Jurij, Han Ruben
Laboratorija za radioizotope, Institut za nuklearne nauke, Vinca.
Med Pregl. 2003 Jul-Aug;56(7-8):362-5. doi: 10.2298/mpns0308362v.
In contemporary nuclear medicine, alpha, pure beta or beta-gamma emitters are used for targeted therapy. Use of pure and combined alpha/beta emitters in oncology, endocrinology, rheumatology and, a short while ago, interventional cardiology, has refined as an important alternative to more common therapeutic regimens. Two radioisotopes of rhenium, rhenium-186 and rhenium-188, are of particular interest. PRODUCTION OF RHENIUM-186 AND RHENIUM-188: Rhenium-186 is routinely produced in nuclear reactors by direct neutron activation of metallic rhenium enriched with 185Re via 185Re(n,) 186Re nuclear reaction. For production of 188Re the target is 186W. 188W is produced by double neutron capture which gives 188Re due to beta decay. Separation of 188Re is performed in generators by column chromatography, extraction or by gel technology. The best results are obtained using chromatographic 188W/188Re generator in which 188W is adsorbed on aluminium. Rhenium-188 is eluted in saline solution.
There are several fields of applications of radiopharmaceuticals labeled with 186,188Re. For bone pain palliation the most often used are 186Re-HEDP and 188Re-DMSA. For synovectomy, 186Re-sulphide in kit form is already commercially available. Endovascular radiation therapy is performed by using 188Re-perrhenate or 188Re-MAG3. Labeling of peptides and antibodies with 188Re is also reported. Application of rhenium radiosotopes depends on their specific activity. Rhenium-186,188 of low specific activity can be used only for labeling of particles or diphosphonates. However, labeling of peptides or antibodies can be performed only by using 188Re of high specific activity.
188Re is expected to have wide applications after development of a chromatographic 188W/188Re generator. One of the advantages of rhenium is tis chemical similarity with technetium. So technetium analogues labeled with 186,188Re can be developed for several specific applications.
在当代核医学中,α、纯β或β-γ发射体被用于靶向治疗。在肿瘤学、内分泌学、风湿病学以及不久前的介入心脏病学中,纯α/β发射体及其组合的应用已发展成为更常见治疗方案的重要替代方法。铼的两种放射性同位素,铼-186和铼-188,尤其受到关注。
铼-186和铼-188的生产:铼-186通常在核反应堆中通过对富含185Re的金属铼进行直接中子活化,经由185Re(n,γ)186Re核反应来生产。对于铼-188的生产,靶材是186W。188W通过双中子俘获产生,由于β衰变而生成188Re。铼-188的分离在发生器中通过柱色谱法、萃取或凝胶技术进行。使用188W吸附在铝上的色谱型188W/188Re发生器可获得最佳结果。铼-188在盐溶液中洗脱。
用186、188Re标记的放射性药物有多个应用领域。用于缓解骨痛最常用的是186Re-HEDP和188Re-DMSA。对于滑膜切除术,试剂盒形式的186Re-硫化物已在市场上有售。血管内放射治疗通过使用188Re-高铼酸盐或188Re-MAG3进行。也有报道用188Re标记肽和抗体。铼放射性同位素的应用取决于它们的比活度。比活度低的铼-186、188仅可用于标记颗粒或二膦酸盐。然而,仅能用比活度高的188Re进行肽或抗体的标记。
预计在开发出色谱型188W/188Re发生器后,铼-188将有广泛应用。铼的优点之一是其与锝的化学相似性。因此,可用186、188Re标记的锝类似物可用于多种特定应用。